News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
24 April 2026

Jabiru-1: Who’s out of orbit?

The financial fallout from NewSat's failed Jabiru-1 satellite project financing could be stratospheric. Investors are claiming $1 billion or more in damages from banks as part...

Video
26 April 2026

EGAP’s CEO on the Czech plan to boost ECA capacity

David Havlíček, CEO of EGAP, the Czech Republic’s export credit agency, discusses the fast evolution of the ECAs’ activity and the pilot plan with the European Investment Bank...